Effect of Colesevelam HCl Monotherapy on Lipid Particles in Type 2 Diabetes Mellitus

详细信息    查看全文

• 作者：Robert S. Rosenson (1)
  Scott P. Rigby (2) (3)
  Michael R. Jones (4) (6)
  Hubert S. Chou (5)
  
• 关键词：Colesevelam ; Monotherapy ; Lipoprotein particles ; Low ; density lipoprotein ; Nuclear magnetic resonance ; Type 2 diabetes mellitus
• 刊名：Cardiovascular Drugs and Therapy
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：28
• 期：3
• 页码：229-236
• 全文大小：191 KB
• 参考文献：1. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496-04. CrossRef
  2. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52(2):453-2. CrossRef
  3. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010;59(5):1153-0. CrossRef
  4. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-2. CrossRef
  5. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106(15):1930-. CrossRef
  6. Ford MA, McConnell JP, Lavi S, Rihal CS, Prasad A, Sandhu GS, et al. Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy. Atherosclerosis. 2009;207(1):111-. CrossRef
  7. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100?mg/dl. Am J Cardiol. 2006;98(12):1599-02. mjcard.2006.07.036" target="_blank" title="It opens in new window">CrossRef
  8. El Harchaoui K, van der Steeg WA, Stroes ESG, Kuivenhoven JA, Otvos JD, Wareham NJ, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;49(5):547-3. CrossRef
  9. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff Jr DC. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105-3. CrossRef
  10. Mackey RH, Greenland P, Goff Jr DC, Lloyd-Jones D, Sibley CT, Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012;60(6):508-6. CrossRef
  11. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113(12):1556-3. CrossRef
  12. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012;125(20):2469-8. CrossRef
  13. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010;213(1):1-. CrossRef
  14. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, Zambon A, et al. “European panel on low density lipoprotein (LDL) subclasses- a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533-1. CrossRef
  15. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013;128(11):1189-7. CrossRef
  16. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975-3. CrossRef
  17. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479-4. CrossRef
  18. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168(14):1531-0. CrossRef
  19. Rosenstock J, Fonseca VA, Garvey WT, Goldberg RB, Handelsman Y, Abby SL, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010;16(4):629-0. CrossRef
  20. Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR. Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus. J Clin Lipidol. 2012;6(4):318-4. CrossRef
  21. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis. 2009;204(2):342-. CrossRef
  22. Rosenstock J, Rigby SP, Ford DM, Tao B, Chou H. The glucose and lipid effects of colesevelam as monotherapy in drug-naive type 2 diabetes. Horm Metab Res. 2013. doi:10.1055/s-0033-1358759 .
  23. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992;38(9):1632-.
  24. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18(7):1046-3. CrossRef
  25. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119(7):931-. CrossRef
  26. Rizzo M, Pernice V, Frasheri A, Di Lorenzo G, Rini GB, Spinas GA, et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol. 2009;70(6):870-. CrossRef
  27. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff Jr DC, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192(1):211-. CrossRef
  28. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32(6):1087-1. CrossRef
  29. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002;90(2):89-4. CrossRef
  30. Rajman I, Kendall MJ, Cramb R, Holder RL, Salih M, Gammage MD. Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men. Atherosclerosis. 1996;125(2):231-2. CrossRef
  31. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006;185(2):327-0. CrossRef
  32. Goldberg RB, Rosenson RS, Hernandez-Triana E, Misir S, Jones MR. Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diab Vasc Dis Res. 2013;10(3):256-2. CrossRef
  33. Krauss RM, Wojnooski K, Orr J, Geaney JC, Pinto CA, Liu Y, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53(3):540-. CrossRef
  34. Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drugs Ther. 2006;20(3):205-7. CrossRef
  35. Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013;304(4):G371-0. CrossRef
  36. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord. 2009;7(3):255-. met.2009.0007" target="_blank" title="It opens in new window">CrossRef
  
• 作者单位：Robert S. Rosenson (1)
  Scott P. Rigby (2) (3)
  Michael R. Jones (4) (6)
  Hubert S. Chou (5)
  
  1. Cardiometabolic Disorders, Mt. Sinai Heart, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, MC1 Level, New York, NY, 10029, USA
  2. Summit Research Group, 4466 Darrow Road, Building B, Suite 5, Stow, OH, 44224, USA
  3. Unity Health Network, LLC, 307 W. Main Street, Suite B, Kent, OH, 44240, USA
  4. Daiichi Sankyo, Inc., 2 Hilton Court, Parsippany, NJ, 07054, USA
  6. Healthcare Consultant, 9156 Pumpkin Ridge, Port St. Lucie, FL, 34986, USA
  5. Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ, 08837, USA
  
• ISSN：1573-7241

文摘

Purpose In addition to lowering hemoglobin A1C, colesevelam has been shown to improve the atherogenic lipoprotein profile of subjects with type 2 diabetes mellitus (T2DM) when used in combination with metformin and/or sulfonylureas. A recent study evaluated the effects of colesevelam as antidiabetes monotherapy in adults with T2DM who had inadequate glycemic control (hemoglobin A1C ?.5 to ?.5?%) with diet and exercise alone; we report here the effects on lipoprotein particle subclasses. Methods Subjects were randomized to receive oral colesevelam 3.75?g/day (n--76) or placebo (n--81) for 24?weeks. Changes in lipoprotein particle subclasses were determined by nuclear magnetic resonance spectroscopy. Results At Week 24 with last observation carried forward, colesevelam produced a reduction in total low-density lipoprotein (LDL) particle concentration (baseline: 1,611?nmol/L; least-squares [LS] mean treatment difference: ?43?nmol/L, p--.0001) versus placebo; reductions were also seen in large, small, and very small LDL particle concentrations (all p--.05). There was also a reduction in total very low-density lipoprotein (VLDL) and chylomicron particle concentration (baseline: 88?nmol/L; LS mean treatment difference: ??nmol/L, p--.82) that resulted from a lowering in small VLDL particle concentration (baseline: 45?nmol/L; LS mean treatment difference: ??nmol/L, p--.03). In addition, with colesevelam there was an increase in total high-density lipoprotein (HDL) particle concentration versus placebo (baseline: 31?μmol/L; LS mean treatment difference: +0.6?μmol/L, p--.20), due to increases in the large (baseline: 5?μmol/L; LS mean treatment difference: +0.5?μmol/L, p--.007) and medium (baseline: 3?μmol/L; LS mean treatment difference: +0.8?μmol/L, p--.02) HDL subclasses. Conclusions Colesevelam monotherapy in subjects with T2DM resulted in generally favorable changes in certain lipoprotein subclass profiles compared with placebo.